Hashim U. Ahmed
Hashim U. Ahmed
Hashim Uddin Ahmed
|Fields||Urology, Urological Oncology|
Hashim U. Ahmed is a British surgeon, medical researcher and author of publications in the field of prostate cancer diagnostics and treatment; his research has contributed to changes in the way men with suspected prostate cancer and men with prostate enlargement are diagnosed and treated. He is Professor and Chair of Urology at Imperial College Healthcare NHS Trust and Consultant Urological Surgeon at both Charing Cross Hospital and BUPA Cromwell Hospital.
He studied medicine at Oxford University, graduating with a BA (Hons) in Physiology in 1998 and completing his medical degree (BM, BCh) in 2001 and has been registered with the GMC since 2001. He completed a Postgraduate Diploma in Clinical Trials at the London School of Hygiene and Tropical Medicine in 2010 and a PhD at University College London in 2013, entitled “The Role of Focal Therapy in the Treatment of Prostate Cancer”.
Professor Ahmed currently divides his time between clinical practice and research, practicing at Charing Cross Hospital and BUPA Cromwell Hospital. As a forerunner in the field of prostate conditions, he is one of the few surgeons offering HIFU (High-intensity focused ultrasound) and cryotherapy for prostate cancer as well as Rezüm water vapor thermal therapy (also known as Prostate steam treatment) for patients diagnosed with prostate enlargement in the UK, with minimal side effects.
Professor Ahmed's research interests lie in advancing diagnostics and treatment of prostate cancer and benign prostate enlargement, to improve life expectancy and quality of life for prostate cancer patients. His research has contributed to the implementation of new diagnostic techniques such as advanced imaging, tissue biomarkers and biopsy techniques, to accurately locate cancerous tissue, improve diagnostic accuracy and inform treatment options. As a direct result of his work, the NHS is piloting a Rapid Access to Prostate Imaging and Diagnosis (RAPID) prostate pathway in which patients receive multi-parametric MRI (mp-MRI) scans prior to biopsy. Ahmed has also worked on innovative, non-invasive treatment techniques that target cancer cells whilst preserving healthy tissue and function, thus leading to fewer side-effects; these treatments include focal high intensity focused ultrasound (HIFU), cryotherapy, radiofrequency ablation, injectable toxins, magnetic thermo-ablation and partial ablation rather than full prostate removal.
- NHS:Professor Hashim U. Ahmed
- Imperial College healthcare: Professor Hashim U. Ahmed
- Cromwell Hospital:Professor Hashim Ahmed, Consultant Urological Surgeon
- List of Registered Medical Practitioners: Dr. Hashim Ahmed
- Ahmed, H. U. (2014-02-28). An evaluation of focal therapy in the treatment of localised prostate cancer (Doctoral thesis). UCL (University College London).
- Prostate Cancer UK: Spotlight on: Professor Hash Ahmed
- Imperial College London: New steam treatment offers hope for men with an enlarged prostate
- The Telegraph: Five-minute steam treatment that shrinks enlarged prostate offers hope for millions of men
- Prostate cancer uk:Focusing on targeted treatments to reduce side effects
- Cancer Therapy Advisor: Men With Prostate Cancer Willing to Accept Worse Survival Odds to Improve QoL
- The Telegraph: Prostate cancer could be ruled out with simple MRI scan which prevents 25,000 biopsies
- NHS England: Implementing a timed prostate cancer diagnostic pathway
- The Guardian: MRI twice as likely as biopsy to spot prostate cancer, research shows
- NHS: RAPID diagnostic prostate cancer pathway
- NHC RM Partners: Professor Hashim Ahmed on the RAPID prostate diagnostic pathway
- Prostate Cancer UK: How playing the long game and your donations led to mpMRI breakthrough
- BBC News: MRI scanning for prostate cancer biggest advance 'in decades'
- National institute for health research: Magnetic Thermoablation in the Treatment of Early Prostate Cancer
- NIHR: A randomised controlled trial of Partial prostate Ablation versus Radical prosTatectomy (PART) in intermediate risk unilateral clinically localised prostate cancer a feasibility study
- NIHR: A randomised controlled trial of Partial prostate Ablation versus Radical Treatment (PART) in intermediate risk, unilateral clinically localised prostate cancer
- Grand Rounds in Uroiogy: Dr. Hashim U. Ahmed on Today’s Focal Therapy For Prostate Cancer